CAMP4 to Participate in Upcoming Investor Conferences
Rhea-AI Summary
CAMP4 (Nasdaq: CAMP) will participate in three investor conferences in March and April 2026, presenting company updates and hosting a fireside chat and corporate presentations.
Events include Leerink Global Healthcare (March 9, 2026, fireside chat, Miami), Stifel CNS Forum (March 17, 2026, virtual) and Needham Healthcare (April 13, 2026, virtual). Live webcasts and 30-day replays will be available on CAMP4's investor relations site.
Positive
- None.
Negative
- None.
News Market Reaction – CAMP
In the Mar 9 session, CAMP gained 49.40%, reflecting a significant positive market reaction. Argus tracked a trough of -4.6% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that the Company will participate in the following upcoming investor conferences:
| Leerink Partners Global Healthcare Conference | |
| Format: | Fireside Chat |
| Date and Time: | March 9, 2026, 8:40 a.m. ET |
| Location: | Miami, FL |
| Webcast Link: | Click Here |
| Stifel CNS Forum | |
| Format: | Corporate Presentation |
| Date and Time: | March 17, 2026, 10:00 a.m. ET |
| Location: | Virtual |
| Webcast Link: | Click Here |
| Needham & Company, LLC 25th Annual Healthcare Conference | |
| Format: | Corporate Presentation |
| Date and Time: | April 13, 2026, 12:45 p.m. ET |
| Location: | Virtual |
| Webcast Link: | Click Here |
Live webcasts can be accessed on the investor relations page of CAMP4’s website at https://investors.camp4tx.com/. A replay of the webcasts will be archived on the CAMP4 website for 30 days following the presentations.
About CAMP4 Therapeutics
CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regulatory RNAs (regRNAs), which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform® enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. For more information, visit camp4tx.com.
Contacts
Investor Relations:
Sara Michelmore
Milestone Advisors
sara@milestone-advisorsllc.com
Media:
Sofia Bermudez
LifeSci Communications
sbermudez@lifescicomms.com
